SAGA appoints Gareth Hoskin to its Board as Non-Executive Director

– UK, Kent – Saga plc (LON:SAGA), the UK’s specialist in products and services for life after 50, today announced the appointment of Gareth Hoskin as Non-Executive Director with effect from 11 March 2019.

Patrick O’Sullivan, Chairman, said: “We are delighted that Gareth will be joining the Board of Saga. We will benefit from his diverse experience at Legal & General across Saga’s businesses and particularly as we continue to develop our insurance business in today’s market.”

About Gareth Hoskin

Gareth spent nearly 20 years with Legal & General in a variety of roles, including as a main Board Director and latterly as CEO International, where he was responsible for the North American, European, Middle East, Indian and Far East insurance markets. Prior to that he held a variety of roles in finance, retail marketing and HR. Before joining Legal & General, Gareth worked at PwC for 12 years, where he trained as an Accountant.

Gareth is currently Audit Chair and Senior Independent Director at Leeds Building Society, the UK’s fifth largest building society, with more than 809,000 members and total assets of £19.5 billion. He is also Trustee, Non-Executive Director and Chair of the Audit and Risk Committees at Diabetes UK Limited.

About Saga plc

Saga is a specialist in the provision of products and services for life after 50. The Saga brand is one of the most recognised and trusted brands in the UK and is known for its high level of customer service and its high quality, award winning products and services including cruises and holidays, insurance, personal finance and publishing.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.